TNFRSF8 and anaplastic large cell lymphoma: Monoclonal antibodies that target CD30, like SGN-30, showed an acceptable safety profile but only modest clinical activity, which has been observed in patients with primary cutaneous ALCL (43% CR rate) and in ALCL patients (17% ORR) (Table 1) [39,40].